Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Atara Biotherapeutics (ATRA) announced that the FDA has placed a clinical hold on Atara’s active investigational new drug, or IND, ...
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...
After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...
--(BUSINESS WIRE)--Atara Biotherapeutics ... These INDs include the EBVALLO TM (tabelecleucel) program as monotherapy treatment for adult and pediatric patients two years of age and older with ...
and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Atara Biotherapeutics (ATRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin ...
Atara Biotherapeutics, Inc. (Nasdaq ... These INDs include the EBVALLO TM (tabelecleucel) program as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein ...
Atara Biotherapeutics, Inc. (Nasdaq ... Screening and enrollment of new participants in both programs have been paused. The clinical hold for EBVALLO is directly linked to inadequately addressed GMP ...
--(BUSINESS WIRE)-- Atara Biotherapeutics ... The clinical hold for EBVALLO is directly linked to inadequately addressed GMP compliance issues identified during the pre-license inspection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback